FLOW - effect of semaglutide v placebo on renal impairment in individuals with type 2 diabetes and chronic kidney disease
University of North Carolina at Chapel Hill
18 - 99 years
Male or female, 18 years or older. Must be diagnosed with type 2 diabetes and have an HbA1c < or = 10%. Must have renal impairment (based on eGFR and UACR). Must be treated with maximum labelled or maximum tolerated RAAS blocking agent, including an ACE inhibitor or ARB.